World2h ago
BioNTech lung cancer drug extends survival versus chemotherapy
Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.
This story was originally reported by The Japan Times. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.
ALSO REPORTED BY OTHER SOURCES (2)
GSKโs Ris-Rez shows survival benefit in lung cancer trial
I had 11 years of chemotherapy for a cancer I didn't have
Community Sentiment & Coverage Reliability
Crowd-sourced evaluation based on verified reader feedback
Rate Coverage Tone:
No reader evaluations recorded yet โ be the first to rate the coverage tone above!
Quick Story Reactions:
Community Discussion (0)
Join the Community Discussion
Sign in or create a free reader account to post comments, upvote analysis, and share your perspective.